Learn More
CERILLIANT™ Lacosamide-13C, D3 Solution, 1.0 mg/mL in Acetonitrile, Sold by MilliporeSigma™ Supelco™
Certified reference material
Supplier: MilliporeSigma Supelco L0321ML
Description
An internal standard suitable for GC/MS or LC/MS applications in lacosamide testing from clinical toxicology and forensic analysis to urine drug testing and isotope dilution methods. Lacosamide is a new antiepileptic drug approved by the FDA in late 2008 for the treatment of partial-onset seizures and diabetic neuropathic pain. The drug is marketed under the trade name Vimpat™.
Specifications
| 75-05-8 | |
| UN 1648 3 / PGII | |
| 254.30 | |
| 1 mL |
| 13CC12D3H15N2O3 | |
| 1.0 mg/mL in acetonitrile | |
| Ampule | |
| 2°C (35.6°F) - closed cup |
Safety and Handling
H332-H319
H312
Recommended Storage : -20°C
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
CERILLIANT is a registered trademark of Cerilliant Corporation